Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFTAZIDIME vs CEFEPIME
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
Treatment of infections caused by susceptible Gram-negative bacteria, including lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bone and joint infections, intra-abdominal infections, central nervous system infections (meningitis), and septicemia.,Empiric therapy for febrile neutropenia.,Off-label: treatment of melioidosis (Burkholderia pseudomallei infection).
1-2 g IV every 8 hours
2 hours (range 1.2-2.2 h) in normal renal function; prolonged to 10-15 h in end-stage renal disease; requires dose adjustment.
Cr Cl 31-50 m L/min: 1 g every 12 hours; Cr Cl 16-30 m L/min: 1 g every 24 hours; Cr Cl 6-15 m L/min: 500 mg every 24 hours; Cr Cl <5 m L/min: 500 mg every 48 hours
No FDA black box warning.
Ceftazidime is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate, well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. Based on available data, ceftazidime does not appear to be associated with major teratogenic effects when used in the first trimester. However, exposure during the second and third trimesters may be considered relatively safe, but data are limited to case reports and small studies.
Ceftazidime is a third-generation cephalosporin with potent activity against Pseudomonas aeruginosa. It is often used in combination with other agents for empiric coverage in febrile neutropenia. Note that ceftazidime has poor activity against gram-positive organisms and anaerobes; consider adding vancomycin or metronidazole if these pathogens are suspected. Dose adjustment is required in renal impairment; calculate Cr Cl before administration. Avoid in patients with cephalosporin allergy or severe penicillin hypersensitivity (risk of cross-reactivity).
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
"Warfarin may increase the anticoagulant activities of Ceftazidime."
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."
CEFTAZIDIME and CEFEPIME are distinct pharmacological agents. CEFTAZIDIME belongs to the Cephalosporin Antibiotic class and is primarily used for Treatment of infections caused by susceptible Gram-negative bacteria, including lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bone and joint infections, intra-abdominal infections, central nervous system infections (meningitis), and septicemia.Empiric therapy for febrile neutropenia.Off-label: treatment of melioidosis (Burkholderia pseudomallei infection).. CEFEPIME belongs to the indicated class and is primarily used for specified clinical guidelines. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. CEFTAZIDIME carries a safety status of Category A/B, whereas CEFEPIME safety is classified as Pending. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Ceftazidime is not metabolized; it is excreted unchanged in the urine via glomerular filtration. Approximately 80-90% of a dose is recovered in the urine within 24 hours.
Primarily renal: 80-90% excreted unchanged in urine via glomerular filtration; small amount (≈1%) biliary; ≤1% fecal.
10-17% (low binding; primarily to albumin).
0.13-0.22 L/kg; low Vd indicates limited tissue penetration; increased in neonates.
IM: 90-100% (well absorbed); IV: 100%.
No adjustment required; see renal adjustment
≥1 month: 30-50 mg/kg IV every 8 hours; max 2 g per dose
Base dose on renal function; see renal adjustment
Hypersensitivity reactions (including anaphylaxis) in patients with penicillin or other beta-lactam allergies; Clostridioides difficile-associated diarrhea; neurotoxicity (seizures, encephalopathy) especially with renal impairment; renal function monitoring; bleeding risk due to hypoprothrombinemia; superinfection; use in pregnancy and lactation.
Hypersensitivity to ceftazidime, any component of the formulation, or other cephalosporins.
No significant food interactions. However, note that alcohol may cause a disulfiram-like reaction (flushing, headache, nausea, vomiting, tachycardia) due to the methylthiotetrazole side chain. Avoid alcohol during therapy and for 48 hours after completion.
Ceftazidime is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.04-0.21. Based on this, the estimated daily dose to the infant is less than 1% of the maternal therapeutic dose. It is considered compatible with breastfeeding by the American Academy of Pediatrics. However, caution is advised, especially in neonates or infants with renal impairment, due to potential for alteration of gut flora and direct effects.
Pharmacokinetic changes in pregnancy include increased volume of distribution and enhanced renal clearance, potentially leading to lower plasma concentrations. However, standard dosing (e.g., 1 g every 8 hours) is generally maintained, as most pathogens remain susceptible. For severe infections, consider higher doses (2 g every 8 hours) or more frequent administration. Monitor clinical response and consider therapeutic drug monitoring if available. No formal dose adjustment guidelines exist for pregnancy.
Take ceftazidime exactly as prescribed; complete the full course even if you feel better.,If you experience severe diarrhea, especially with blood or mucus, contact your doctor immediately.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Avoid alcohol during treatment and for at least 48 hours after the last dose to prevent disulfiram-like reaction.,Notify your doctor if you have a history of penicillin allergy or kidney disease.